A phase I Clinical Study evaluating LNK01001 in healthy subjects
Latest Information Update: 21 Jan 2022
At a glance
- Drugs LNK 01001 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Lynk Pharmaceuticals
Most Recent Events
- 21 Jan 2022 New trial record
- 01 Dec 2021 According to Lynk Pharmaceuticals media release, this study was completed in summer 2021, sponsored by Lynk Pharmaceuticals and its US partner